Publication | Open Access

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

OncologyPolymer-drug ConjugateMedicineFirst-in-human Phase 1/2ATumor TargetingAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer Research